Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity

Sedigheh Shams1,2,3, Maliheh Barazandeh Tehrani4*, Gabriel Civallero5, Koosha Minookherad4, Roberto Giugliani5,6, Aria Setoodeh7 and Mohammad Taghi Haghi Ashtiani1,2

Abstract

Background: Mucopolysaccharidosis type IVA, also known as Morquio A or MPS IV A, is an autosomal recessive disease caused by the deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). The loss of GALNS activity leads to the impaired breakdown of glycosaminoglycans (GAGs) keratan sulfate and chondroitin-6-sulfate. The accumulation of GAGs results in multiple organ damage. The accurate and early diagnosis of this disorder helps enhance the effectiveness of the treatment. The present study uses a pre-designed protocol for testing GALNS activity in the leukocytes of Iranian patients with MPS IV A and their parents and compares it with healthy controls.

Methods: Patients with MPS IVA previously diagnosed through the measurement of enzyme activity or genetic analysis entered the study. Leukocytes were obtained from the heparinized blood of the participants. The GALNS activity was measured by a fluorometric method using 4-methylumbelliferyl-β-D-galactoside-6-sulfate (4MU-G6S) as the substrate and proper buffer solutions and calibrators.

Results: The GALNS activity (nmol/17 h/mg protein) was reported as 0–7.4 in the MPSIV A patients, as 19.85–93.7 in their parents and as 38.4–164 in the healthy controls. Statistically significant differences were observed between the three groups in terms of enzyme activity. There were no significant differences in enzyme activity by age. The female subjects in both the patient and parents groups showed lower enzyme activity compared to the male subjects.

Conclusion: The fluorometric method was validated for the measurement of GALNS activity in leukocyte samples and identifying Iranian patients with MPS IV A.

Keywords: MPS IV A, Mucopolysaccharidosis, Morquio A, Enzyme assay, GALNS deficiency

Background

Mucopolysaccharidosis type IV-A (OMIM #253000) or Morquio syndrome type A or simply MPS IV A is an autosomal recessive disease caused by the deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Due to the deficiency of this enzyme, glycosaminoglycans (GAGs) such as keratan sulfate (KS) and chondroitin-6-sulfate (CS) are not decomposed and instead accumulate in different organs. The accumulation of GAGs in different organs causes many clinical manifestations, including skeletal, cardiopulmonary and visual disorders. Skeletal disorder symptoms begin mainly with short stature and dysostosis multiplex. The height does not exceed 113–123 cm in patients with MPS IV A and the disease is often diagnosed with kyphosis, pigeon chest deformity, kyphoscoliosis and facial deformities. Unlike other mucopolysaccharidosis, in which the patients suffer from joint stiffness, patients with this disease have joint hypermobility due to ligamentous laxity. This condition makes walking difficult for the patients and has significant adverse effects on...
their quality of life. Dental problems are also characteristic of this disease. Patients with MPS IV A are cognitively and developmentally normal. Although patients with MPS IV-B (OMIM#253010) are phenotypically similar to those with MPS IV A and excrete KS as well, their disorder is caused by the deficiency of β-galactosidase [1–5]. To date, over 220 mutations in the GALNS gene have been reported. Multiple mutations lead to the emergence of different phenotypes of this disease that makes the clinical diagnosis of the condition difficult, especially since many of its clinical symptoms are also observed in other types of MPS. In 2013, a group of scientists from different countries developed a guideline for the diagnosis of the disease so that physicians and laboratory directors can make an accurate and early diagnosis of the disease [2, 6, 7].

The screening methods used for the diagnosis of this disease include the analysis of GAGs in urine and the measurement of the enzyme activity in dried blood spots (DBS). Detecting the type of MPS excretion contributes significantly to the diagnosis of the disease, although it is not a very specific criterion. The absence of GAGs from the urine does not exclude the possibility of MPS IV A [8–13].

The final diagnosis is made by measuring enzyme activity in the leukocytes (whole blood) or fibroblasts (skin) and molecular tests can also confirm the diagnosis. In the case of a reduced enzyme activity in the fibroblast sample, Multiple Sulfatase Deficiency (MSD) should be ruled out. Until recently, patients with this disease received only supportive care; however, in February 2014, the FDA approved the use of enzyme replacement therapy (ERT) with Elosulfase for treating this disease [14–16]. Given that the disease is progressive and irreversible, its early diagnosis and treatment can help improve the effectiveness of the treatment. Furthermore, accessing diagnostic methods for individuals with a family history of the disease is very helpful. There are no precise statistics on the prevalence of MPS in Iran; however, it is likely more prevalent than the estimates due to the abundance of consanguineous marriages in the country. The present study was conducted to determine the activity of GALNS in healthy individuals and patients with MPS IV A and their parents for the first time in Iran so as to provide a more affordable method of diagnosis and to ease the access to the biochemical identification of the disease and enable its prenatal diagnosis across the entire country. To accomplish these goals, a fluorometric method previously presented was used in this study with slight changes [17].

Methods
Study subjects
The study subjects consisted of 12 patients with a Morquio A (MPS IV A) previously diagnosed with this disease through the measurement of enzyme activity or genetic studies performed outside Iran. A total of 11 parents of the patients also participated in the study, and two families had more than one child with this disease.

The control group consisted of a total of 20 healthy randomly-selected subjects who entered the study upon providing their informed consent. The patients and their parents also provided their written consent for participation in the study. This descriptive study was conducted at Children’s Medical Center, a referral teaching hospital in Tehran, in 2016. The study was approved by the Ethics Committee of Tehran University of Medical Sciences. The researchers complied with the ethical principles of the Declaration of Helsinki, including the confidentiality of the data, giving the physician in charge access to the lab test results if needed and not charging the patients for the study procedures.

Reagents and solutions
The reagents used included dextran, albumin, sodium acetate, sodium azide, β-galactosidase galactohydrolase and 4- methylumbelliferone (calibrator) and were purchased from Sigma Co. The other reagents used were from Merck Co. The protein measurement kit was made in Iran by Pars Azmoon. The 4-Methylumbelliferyl β-D-Galactopiranoside-6-sulfate substrate was purchased from Sigma Co. and from Toronto Research Chemicals (TRC) in Toronto, Canada.

Enzyme activity measurement
Five milliliters (5 ml) of heparinized blood was drawn from the participants and their leukocytes were immediately separated after adding an equal volume of 6% dextran (Sigma D-4876, Mw 150.000) using the method proposed by Diggelen and Skoog et al. [17, 18]. The separated leukocytes were sonicated with 500 μl of distilled water and then centrifuged so as to measure their protein concentration with a pyrogallol red-molybdate complex using a Vitalab Selectra E, Vital Scientific N. V. autoanalyzer. The samples were kept at –20 °C until the tests began. The enzyme activity was measured using the methods proposed by Diggelen and Camelier [17, 19] with slight changes. To summarize the measurements, 20 μl of the sample diluted with albumin solution (0.2% BSA and 0.2% Sodium Azide) and 40 μl of the substrate were incubated in a shaking bath at 37 °C for 17 h. In the second step, 10 μl of phosphate buffer solution and 20 μl of β-galactosidase galactohydrolase were added and the incubation continued for 2 h. Exogenous galactosidase was added to inhibit the effect of a potential galactosidase deficiency on the test results. The reaction was then stopped by adding carbonate buffer, centrifuged at 3000 rpm and the fluorescence was measured. The blank solution was made with the addition of the
albumin solution instead of the sample (Table 1). The enzyme activity was measured using a calibration curve at different concentrations of 4-methylumbelliferone and reported in nmol/17 h/mg protein. The fluorescence of the samples and the calibrator was measured using a fluorometer (Model 450, Sequoia-Turner) at the excitation and emission wavelengths of 390 nm and 500 nm, respectively.

The inter-assay variation coefficient was calculated through measuring the enzyme activity of the three samples on five different days. The intra-assay CV was calculated through measuring the enzyme activity of the three samples three times and in the same run.

### Statistical data analysis

The data obtained were analyzed in SPSS-17. The Kolmogorov-Smirnov test was used to examine the normal distribution of the data. The descriptive data were reported as mean ± standard deviation and minimum and maximum values for the quantitative data and as percentage for the qualitative variables.

The ANOVA and Bonferroni’s post-hoc tests were used to find statistical differences between the groups. The correlation coefficient was used to find correlations, if any, between the quantitative variables. $P < 0.05$ was considered as the level of statistical significance.

### Results

The present study was conducted on a total of 43 individuals, including 12 patients aged 1.5–24, 11 of their parents aged 25–58, and 20 seemingly healthy individuals aged 1.5–54 years old. The enzyme activity of the leukocytes was measured in the participants. The mean enzyme activity differed significantly between the three groups and was significantly lower in the group of patients compared to the other two groups and was also 50% less in the group of parents compared to the control group. The patients’ results did not overlap with the results of the other two groups in any aspect; however, an overlap was observed between the control group and the group of parents. Table 2 presents the distribution of the participants in the groups, their demographic data and the measured parameters.

The enzyme activity was examined in and between the three groups by gender. The mean enzyme activity was lower in women than in men in the group of patients and parents, but higher in women than in men in the control group; however, the difference was not statistically significant (Table 3).

The comparison of the three groups showed that the mean enzyme activity differed significantly between the female patients and their mothers (carriers) and the female controls. The mean enzyme activity in the female carriers was 50% less than that in the female controls.

The difference between the mean enzyme activity of the male carriers and the male controls was not statistically significant ($P = 0.743$); however, the male patients differed significantly in this regard from both the fathers of the patients and the male controls. The mean enzyme activity in the group of fathers was 75% as that in the male controls. No correlations were observed between the mean enzyme activity and age in the study groups.

The mean coefficient of variation was 7.3% for the assays in the same day and 22% for the assays in different days.

### Discussion

The present study is the first in Iran to have examined the GALNS activity in healthy individuals and patients with MPS IVA and their parents. A fluorogenic substrate and leukocytes separated from heparinized blood were used for this purpose. The results enabled the accurate differentiation of patients from healthy subjects and carriers.

Diggelen et al. synthesized the fluorogenic substrate 4-MU-Gal-6-S for the first time in 1990 and used it to diagnose enzyme deficiency in patients with Morquio A disease. This method did not require the substrate to be separated and was more sensitive and economical than the radioactive substrate method. The fluorogenic substrate used in the present study also revealed a significant difference between the three groups.

In the study by Diggelen, the mean enzyme activity of the parents was 50% as that of the healthy population, which is consistent with the present study, which found that the mean enzyme activity of the parents was 50% as that of the controls. In the present study, the enzyme activity was lower than the control’s mean activity in more
The mean enzyme activity was lower in women than in men in the group of patients and their parents; in the control group, however, it was slightly higher in women than in men, although the difference was not statistically significant. No gender-based comparisons were performed in Diggelen’s study and the other reports. The enzyme activity may vary with the particular mutation of GALNS, and patients differ significantly in terms of clinical symptoms and age at the onset of symptoms by their type of mutation [20]. Only a few of the patients and none of the parents in this study had undergone genetic testing. Explaining the differences in enzyme activity and its relationship to clinical symptoms requires molecular testing. Due to the small sample size of the study and the high volume of blood required. Similar to any other sulfatase, finding a deficient activity requires the measurement of other sulfatases to exclude the possibility of multiple sulfatase deficiency [2].

With the emergence of new treatments, the accurate and early diagnosis of MPS IV-A becomes necessary. Camelier et al. adapted Diggelen’s method to measure the enzyme activity in DBS [19]. This procedure, later improved on by Ullal et al. [21], not only facilitates the collection and delivery of samples to the referential laboratory for testing, but also make this procedure more suitable for the neonatal screening of MPS IV A. Recently, a study conducted by Cozma et al., measured GALNS activity on a DBS using a fluorogenic substrate and measured the reaction product by LC/MS-MS [22]. Extending the results of this study to newborns can be a potentially effective tool for neonatal screening.

**Conclusion**

A GALNS measurement method was validated in this study at a university referral center in Iran for the first time.
time to help enable the diagnosis of patients with MPS IV A and determine the values of enzyme activity in healthy subjects in Iran. A study with a larger sample size is required to determine the reference interval for GALNS activity in healthy Iranian subjects. More studies with larger sample sizes are required on the effectiveness of this enzyme assay as a method for identifying carriers.

Acknowledgments
The authors would like to express their gratitude to all the physicians and patients who helped conduct this study, especially to Dr. P. Rostami and Dr. F. Abbasi. This research project was funded by Tehran University of Medical Sciences (Project Number: 94-03-30-30170). The authors would also like to thank all the staff at the Clinical Laboratory of the Children’s Medical Center, especially Neda Rezaei, Heshmat Irani, Samaneh Baghian, Leila Shafeghat and Mohsen Savashi, for the collection and processing of the blood samples.

Funding
This research project was funded by Tehran University of Medical Sciences (Project Number: 94–03–30–30-170).

Availability of data and materials
Please contact the author for data requests.

Authors’ contributions
SSH and MBT participated in the design of the study, interpretation of the data and drafting of the manuscript. GC and RG supervised all the experiments and approved the manuscript. KM carried out all the experiments and performed the statistical analysis. AS and MTHA participated in the coordination of the research and the drafting of the manuscript. All the authors read and approved the final manuscript.

Ethics approval and consent to participate
This research was approved by the Research Committee of Tehran University of Medical Sciences under the approval code IR.TUMS.1394.1619.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran. 3 Pediatric Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4 Pediatric Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 5 Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran. 6 Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. 7 Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 8 Division of Pediatrics Endocrinology, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.

Received: 1 March 2017 Accepted: 3 September 2017

Published online: 08 September 2017

References
1. Hendrickz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110(1-2):54–64. doi:10.1016/j.ymgme.2013.04.002.
2. Wood TC, Harvey K, Beck M, Burin MG, Chien YH, Church HJ, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36(2):293–307. doi:10.1007/s10545-013-9587-1.
3. Tomatsu S, Fujii T, Fukushima M, Oguama T, Shimada T, Maeda M, et al. Newborn screening and diagnosis of mucopolysaccharidosis. Mol Genet Metab. 2013;110(1–2):42–53. doi:10.1016/j.ymgme.2013.06.007.
4. Khedhiri S, Chkioua L, Bouzidi H, Dandana A, Ben Turkia H, Miled A, Laradi S. Mucopolysaccharidosis type I and IVA: clinical features and consanguinity in Tunisia. Pathol Biol (Paris). 2009;57(3):392–397. doi:10.1016/j.patbio.2008.05.005.
5. Bhattacharya K, Balasubramaniam S, Cho Y, S Fritz, M, Fu A, Jin DK, et al. Overcoming the barriers to diagnosis of Morquio A syndrome. Orphanet J Rare Dis. 2014;3009:192. doi:10.1186/1750-1172-11-192.
6. Khedhiri S, Chkioua L, Eligioli N, Laradi S, Miled A. Mutations and polymorphisms in N- acetylgalactosamine-6-sulfate sulfatase gene in Turkish Morquio A patients. Pathol Biol (Paris). 2014;62(11):s38–40. doi:10.1016/j.patbio.2013.10.001.
7. Morrone A, Tylee KL, Al-Sayed M, et al. Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol Genet Metab. 2014;112(2):160–70. doi:10.1016/j.ymgme.2014.03.004.
8. Berry HK. Screening for mucopolysaccharide disorders with the berry spot test. Clin Biochem. 1987;20(3):365–71.
9. Whiteley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP. Diagnostic test for Mucopolysaccharidosiis. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem. 1989;35(3):374–9.
10. Mabe F, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylhydantoin blue and Berry spot tests. Clinica chimica acta; international journal of clinical chemistry. 2004;345(1–2):1135–40.
11. Zaia J. Principles of mass spectrometry of glycosaminoglycans. Journal of Biomacromolecular Mass Spectrometry. 2005;11(1):3–36.
12. Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidosis. Orphanet J Rare Dis. 2014;19(9):135. doi:10.1186/1750-1172-10-135.
13. Tomatsu S, Shimada T, Mason RW, Kelly J, Lam WA, Yasuda E, et al. Assay of Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech. 2014, 02; doi:10.4172/2155-9872.52-006.
14. Haddley K. Elosulfase Alfa. Drugs Today (Barc). 2014;50(7):475–83. doi:10.1385/DT:2014.7.2177904.
15. Schweighardt B, Tompkins T, Lau K, Jaspers L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther. 2015;37(5):1012–1021.e6. doi:10.1016/j.clinthera.2015.06.005.
16. Burton BK, Berger RI, Lewis GD, Tarnopolsky M 5, Treadwell M 6, Mitchell JJ, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio A syndrome: A randomized, double-blind, pilot study. Am J Med Genet A. 2015;167A(1):227–81. doi:10.1002/ajmg.a.37172.
17. Van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Pootuijs BvJHM, Van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IVa). Clinica Chimica Acta. 1990;187(1):131–40.
18. Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytosaponin method of isolating leukocytes. Blood. 1956;11(436–54.
19. Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Guigliani R. Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood spots. Clin Chim Acta. 2011;412(19-20):1808–1810. doi:10.1016/j.cca.2011.06.001.
20. Olarte-Avelaned a S, Rodr guez-Lopez A, Almeciga-Diaz CJ, Barrera LA. Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype–phenotype correlation for Morquio A. Mol Biol Rep. 2014;41(7):703–88. doi:10.1007/s11033-014-3383-3.
21. Ullan AJ, Millington DS, Bale DS. Development of a fluorometric microtiter plate based enzyme assay for MPS IV (Morquio type A) using dried blood spots. Molecular Genetics and Metabolism Reports. 2014;1:461–464. doi:10.1016/j.ymgmr.2014.10.004.
22. Cozza C, Eichert S, Wittmann G, Flores Bonet A, Kamp Gi, Giese AK, et al. Diagnosis of Morquio syndrome in dried blood spots based on a new MRIM-MS assay. PLoS One. 2015;10(7):e0131228. doi:10.1371/journal.pone.0131228. eCollection 2015.